SalubrisBio
Overview
Salubris Biotherapeutics, Inc. (SalubrisBio) is a clinical-stage biotechnology company focused on the discovery and development of complex biologics targeting cardiovascular, oncology, and neurodegenerative diseases. Founded in August 2016 as a wholly-owned subsidiary of Shenzhen Salubris Pharmaceuticals Co. Ltd., SalubrisBio is headquartered in Gaithersburg, Maryland. The company has raised significant funding for its innovative research and development endeavors, most recently securing $35 million in April 2024 to advance its clinical programs.
Recent Developments
-
August 2024: SalubrisBio received approval from the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial for JK06, a pioneering quadrivalent, biparatopic antibody-drug conjugate (ADC). The trial will target solid tumors expressing the 5T4 protein, known for its association with poor prognosis in cancers like lung and breast cancer. JK06 has shown promising efficacy and safety profiles in preclinical studies, and the clinical trial aims to evaluate these further in human subjects.
-
April 2024: The company announced a new capital infusion of $35 million to support ongoing research and development in innovative biologic therapeutics. This includes JK07, an investigational antibody fusion protein for heart failure, and JK08, an IL15-CTLA4 antibody fusion for cancer treatment. Additionally, SalubrisBio's clinical trial for JK07 is progressing, with its first patient enrolled in the Phase 2 clinical trial aiming to address heart failure with preserved and reduced ejection fraction.
-
October 2023: Positive initial data from the Phase 1b/2 clinical trial of JK08 was presented at the European Society for Medical Oncology Annual Congress, highlighting the drug's potential anti-tumor activity in cancer treatment.
-
October 2023: In another key update, SalubrisBio reported positive six-month data from the Phase 1b clinical trial of JK07 at the Heart Failure Society of America Annual Meeting, indicating substantial improvement in heart function and patient outcomes.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | August 2016 |
| Headquarters | Gaithersburg, Maryland, United States |
| Founders | Not specified |
| Revenue | Not publicly available |
| Profits | Not publicly available |
| Key Investors | Shenzhen Salubris Pharmaceuticals |
| Industry | Biotechnology |
| Number of Employees | Not publicly available |
Early History
Established in 2016 as a subsidiary of Shenzhen Salubris Pharmaceuticals, SalubrisBio was founded with a strategic focus on expanding its parent company’s innovative footprint into the global biotechnology market. SalubrisBio was created to develop novel therapeutic agents with substantial unmet medical needs for large patient populations. By leveraging its parent company’s resources and expertise, SalubrisBio quickly developed a pipeline of biologic drugs, including JK07 and JK06, which are positioned as first-of-their-kind therapies in the areas of heart failure and oncology, respectively.
Company Profile and Achievements
SalubrisBio adopts a comprehensive business model focused on the development of biologic therapeutics using proprietary technologies and research expertise. Its portfolio features several groundbreaking drug candidates:
- JK06: A biparatopic ADC targeting the 5T4 protein, innovative in therapy for multiple solid tumors.
- JK07: A recombinant fusion protein for heart failure; shows promise as the first disease-modifying biologic therapy in this condition with potential improvements in quality of life and patient outcomes.
- JK08: Combines IL15 and CTLA4, two potent immune-stimulating agents, to potentially expand treatment options for solid tumors.
SalubrisBio’s methodical approach to drug development involves rigorous trials and partnerships with reputable clinical research organizations. It has achieved multiple milestones, including successful completion of various clinical trial phases and international regulatory approvals, and continues to secure capital investments to fuel its pipeline development.
Current Operations and Market Position
SalubrisBio is a prominent player in the biotechnology industry with clear emphasis on biologics for challenging diseases. It holds strategic advantages through its robust research and development pipeline and commitment to addressing unmet medical needs. Recent strategic initiatives involve expanding clinical trials and solidifying partnerships to enhance its therapeutic offerings, particularly in cardiovascular and oncology segments. SalubrisBio continues to strengthen its market position through innovative approaches and significant financial supports.
Conclusion
Salubris Biotherapeutics, Inc. stands out in the biotechnology sector for its pioneering work in developing cutting-edge biologic therapies. With a strong commitment to innovation and addressing significant health challenges, SalubrisBio positions itself as a crucial player striving to offer first-of-their-kind therapies for diseases such as heart failure and cancer. As it progresses its clinical trials and development pipeline, the company's future trajectory includes expanding its market presence and establishing itself as a leader in complex biologics, potentially transforming treatment paradigms in key therapeutic areas.